Biomarkers in chronic spontaneous urticaria for omalizumab drug survival: a retrospective analysis

Aydoğdu, Ceyda; Alataş, Emine; Pektaş, Suzan; YÜREKLİ, Aslan; Daşgın, Dilek; Chakmakchi, Ahmed; Muslu, İlayda; Özdemir, Himmet; Köroğlu, Alp

doi:10.1093/ced/llaf353

Biomarkers in chronic spontaneous urticaria for omalizumab drug survival: a retrospective analysis

Aydoğdu C. T., Alataş E. T., Pektaş S. D., YÜREKLİ A., Daşgın D., Chakmakchi A., ...Daha Fazla

Clinical and Experimental Dermatology, cilt.51, sa.1, ss.110-111, 2026 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Kısa Makale
Cilt numarası: 51 Sayı: 1
Basım Tarihi: 2026
Doi Numarası: 10.1093/ced/llaf353
Dergi Adı: Clinical and Experimental Dermatology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
Sayfa Sayıları: ss.110-111
Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

This study aimed to evaluate drug survival after omalizumab treatment by using biomarkers. Findings suggest that eosinopenia/basopenia may predict shorter omalizumab drug survival. High baseline total IgE levels are associated with higher relapse rates after treatment cessation in patients with chronic spontaneous urticaria.